StreetInsider.com News Articles

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Thu, 22 Oct 2026 07:30:00 -0400

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its third quarter 2026 financial results and business update after the market closes on Thursday, October 29, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Thu, 22 Oct 2026 07:30:00 -0400

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at

BridgeBio Pharma (BBIO) PT Lowered to $87 at Morgan Stanley

Wed, 21 Oct 2026 08:21:10 -0400

Morgan Stanley analyst Sean Laaman lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $87.00 (from $97.00) while maintaining a Overweight rating.

BridgeBio Pharma (BBIO) PT Raised to $120 at Piper Sandler

Mon, 19 Oct 2026 07:13:17 -0400

Piper Sandler analyst Biren Amin raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $120.00 (from $115.00) while maintaining a Overweight rating.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 07:30:00 -0400

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on October 14, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 32 new employees in restricted stock units for an aggregate of 57,853 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 07:30:00 -0400

BridgeBio Pharma (BBIO) PT Raised to $92 at UBS

Thu, 15 Oct 2026 09:12:54 -0400

UBS analyst Joon Lee raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $92.00 (from $82.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Thu, 15 Oct 2026 06:57:02 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $120.00 price target on BridgeBio Pharma (NASDAQ: BBIO).

The analyst commented: "Encaleret pivotal program data strengthens positioning in ADH1 and may bode well for future label expansion. Late last week, BridgeBio presented bone turnover results and patient-reported outcomes from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The data were presented in oral presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting in Boston, MA. Erik Imel, M.D. of Indiana University School of Medicine, presented an oral presentation on 24-week

Form 8-K BridgeBio Pharma, Inc. For: Oct 06

Tue, 13 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27176290.html

Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'

Mon, 12 Oct 2026 09:04:19 -0400

Truist Securitas's Biotechnology Earnings Preview

The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.